{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:32:16Z","timestamp":1786433536062,"version":"build-2736575974"},"reference-count":8,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"DOI":"10.1177\/10600280261476305","type":"journal-article","created":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T07:04:58Z","timestamp":1786259098000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bulevirtide (Hepcludex) for Chronic Hepatitis Delta: A Milestone Achievement Demanding Real-World Evaluation"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3865-3790","authenticated-orcid":false,"given":"Aun Muhammad","family":"Shoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9646-7180","authenticated-orcid":false,"given":"Sufwan Ullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,9]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.008"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed9040073"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00318-8"},{"key":"e_1_3_2_5_2","unstructured":"CHMP. Hepcludex INN-Bulevirtide. Hepcludex (bulevirtide): European public assessment report [Internet]. European Medicines Agency; 2024. Accessed July 31 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hepcludex"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213429"},{"key":"e_1_3_2_7_2","unstructured":"FDA News Release. FDA approves first treatment for chronic hepatitis delta virus (HDV) infection. U.S. Food and Drug Administration; May 22 2026. Accessed July 31 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-chronic-hepatitis-delta-virus-hdv-infection"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16174"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/v17020251"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261476305","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261476305","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261476305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:19:04Z","timestamp":1786432744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261476305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,9]]},"references-count":8,"alternative-id":["10.1177\/10600280261476305"],"URL":"https:\/\/doi.org\/10.1177\/10600280261476305","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,9]]},"article-number":"10600280261476305"}}